首页> 外文期刊>International Journal of Pharmacy and Pharmaceutical Sciences >QUALITY OF LIFE OF CHRONIC KIDNEY DISEASE PATIENTS WITH ROUTINE HEMODIALYSIS IN GENERAL HOSPITALS IN SLEMAN YOGYAKARTA
【24h】

QUALITY OF LIFE OF CHRONIC KIDNEY DISEASE PATIENTS WITH ROUTINE HEMODIALYSIS IN GENERAL HOSPITALS IN SLEMAN YOGYAKARTA

机译:约克雅特地区普通医院慢性肾病患者常规血液透析的生存质量

获取原文
       

摘要

Objective : To elicit quality of life (QOL) of chronic kidney disease (CKD) patients with routine hemodialysis receiving erythropoietin, to compare the QOL of CKD patients with routine hemodialysis receiving different erythropoietin, and to explore the change in QOL over six months for patients managed in the hospitals. Methods : A multicenter prospective study was conducted among adult CKD patients in Yogyakarta. QOL was measured using kidney disease quality of life–short form (KDQOL–SF TM ) questionnaire and a FACIT fatigue scale questionnaire. CKD patients were divided into 2 groups: those receiving erythropoietin alpha (n=74) and those receiving erythropoietin beta (n=39). Both groups were asked to complete the KDQOL–SF TM questionnaire and a FACIT fatigue scale questionnaire two times in six months range. Results : In the first period, the average rate of the KDQOL-SF and FACIT for CKD patients receive erythropoietin alpha compared to CKD patients receive erythropoietin beta was 77.24: 80.21 and 3.35: 3.49 while in the second period, the average rate of the KDQOL-SF and FACIT for CKD patients receive erythropoietin alpha compared to CKD patients receive erythropoietin beta was 80.45: 83.95 and 3.45: 3.56. Conclusion : Erythropoietin can improve QOL of CKD patients with routine hemodialysis, while erythropoietin beta gives more improvement, but statistically, it doesn’t different significantly.
机译:目的:探讨接受促红细胞生成素的常规血液透析的慢性肾脏病(CKD)患者的生活质量(QOL),比较接受不同促红细胞生成素的常规血液透析的CKD患者的QOL,并探讨患者六个月以上QOL的变化在医院管理。方法:对日惹成年CKD患者进行了多中心前瞻性研究。使用肾脏疾病生活质量简表(KDQOL–SF TM)问卷和FACIT疲劳量表问卷来测量QOL。 CKD患者分为两组:接受促红细胞生成素α的患者(n = 74)和接受促红细胞生成素β的患者(n = 39)。两组均要求在六个月内两次完成KDQOL-SF TM问卷和FACIT疲劳量表问卷。结果:第一阶段,接受促红细胞生成素α的CKD患者的KDQOL-SF和FACIT的平均发生率,与接受促红细胞生成素β的CKD患者的平均发生率分别为77.24:80.21和3.35:3.49,而在第二阶段,KDQOL的平均发生率接受促红细胞生成素α的CKD患者的-SF和FACIT与接受促红细胞生成素β的CKD患者的β为80.45:83.95和3.45:3.56。结论:促红细胞生成素可以改善常规血液透析患者的CKD患者的QOL,而促红细胞生成素β可以改善患者的生活质量,但从统计学上看,两者没有显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号